MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.443
EU - Europa 5.932
AS - Asia 3.140
OC - Oceania 429
AF - Africa 140
SA - Sud America 101
Continente sconosciuto - Info sul continente non disponibili 10
Totale 22.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.075
GB - Regno Unito 2.407
IT - Italia 858
CN - Cina 565
SE - Svezia 554
DE - Germania 549
AU - Australia 397
HK - Hong Kong 385
TR - Turchia 366
PH - Filippine 344
CA - Canada 315
FR - Francia 267
UA - Ucraina 246
IR - Iran 232
SG - Singapore 209
FI - Finlandia 170
IN - India 129
BG - Bulgaria 108
IE - Irlanda 108
ID - Indonesia 99
PK - Pakistan 97
JP - Giappone 88
VN - Vietnam 86
NL - Olanda 80
ES - Italia 76
MY - Malesia 73
TW - Taiwan 71
KR - Corea 68
IL - Israele 67
PL - Polonia 58
RU - Federazione Russa 58
GR - Grecia 57
BE - Belgio 56
SA - Arabia Saudita 48
BR - Brasile 47
TH - Thailandia 43
GE - Georgia 38
NP - Nepal 37
NO - Norvegia 36
RO - Romania 35
NZ - Nuova Zelanda 32
ZA - Sudafrica 31
AT - Austria 27
CH - Svizzera 26
KE - Kenya 25
MA - Marocco 24
LT - Lituania 22
MX - Messico 21
JO - Giordania 19
CZ - Repubblica Ceca 18
EE - Estonia 18
LK - Sri Lanka 16
BZ - Belize 14
HR - Croazia 14
PT - Portogallo 14
SI - Slovenia 14
SK - Slovacchia (Repubblica Slovacca) 14
CL - Cile 13
HU - Ungheria 12
NG - Nigeria 12
DK - Danimarca 9
EC - Ecuador 9
PE - Perù 9
AR - Argentina 8
EG - Egitto 8
LV - Lettonia 8
TN - Tunisia 8
CY - Cipro 7
PR - Porto Rico 7
A2 - ???statistics.table.value.countryCode.A2??? 6
MO - Macao, regione amministrativa speciale della Cina 6
AE - Emirati Arabi Uniti 5
BD - Bangladesh 5
CO - Colombia 5
ET - Etiopia 5
GY - Guiana 5
KZ - Kazakistan 5
MU - Mauritius 5
MV - Maldive 5
OM - Oman 5
EU - Europa 4
IQ - Iraq 4
KW - Kuwait 4
NA - Namibia 4
QA - Qatar 4
SD - Sudan 4
GH - Ghana 3
GP - Guadalupe 3
RS - Serbia 3
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
LU - Lussemburgo 2
MD - Moldavia 2
MT - Malta 2
MW - Malawi 2
PS - Palestinian Territory 2
SC - Seychelles 2
SO - Somalia 2
Totale 22.173
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Woodbridge 1.142
Ashburn 984
Chandler 839
Houston 809
Seattle 677
Wilmington 643
Cambridge 587
Jacksonville 503
Dearborn 428
Ann Arbor 404
Nyköping 401
Hong Kong 321
Modena 223
Beijing 195
Redwood City 183
San Diego 177
Frankfurt am Main 170
New York 151
Izmir 140
Singapore 119
Princeton 116
Sofia 106
London 101
Eugene 96
Helsinki 89
Melbourne 83
Shanghai 68
Bremen 59
Milan 56
Dublin 53
Ottawa 50
Falls Church 46
Jakarta 46
Bologna 45
Istanbul 43
Taipei 43
Sydney 41
Brisbane 39
Fremont 37
Paris 37
Des Moines 36
Brussels 34
Dong Ket 34
Norwalk 28
Tehran 28
Perth 27
Phoenix 26
Hanoi 25
Tokyo 25
Nanjing 24
San Giuliano Milanese 24
Islamabad 23
Greenwich 22
Laval 22
San Jose 22
Tbilisi 22
Birmingham 21
Kathmandu 21
Boardman 20
Chicago 20
Parma 20
Quezon City 20
Rome 20
Toronto 20
Manila 19
Cebu City 18
Ho Chi Minh City 17
Karachi 17
Kuala Lumpur 17
Kunming 17
Riyadh 17
Athens 16
Ankara 15
Auckland 15
Banqiao 15
Delhi 15
Tralee 15
Warsaw 15
Antalya 14
Belize City 14
Guangzhou 13
Nairobi 13
Saint Petersburg 13
San Francisco 13
San Mateo 13
Tappahannock 13
Bangkok 12
Cagayan de Oro 12
Eastbourne 12
Hounslow 12
Kilburn 12
Munich 12
Palermo 12
Seoul 12
Augusta 11
Buffalo 11
Davao City 11
Edinburgh 11
Totale 14.842
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 5.243
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 516
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 513
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 504
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 308
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 279
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 240
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 236
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 234
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 232
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 231
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 229
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 226
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 222
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 222
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 218
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. 212
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 209
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 207
Empathic attitudes among nursing students: a preliminary study 206
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 206
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 205
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 201
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 199
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 195
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 194
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 192
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 189
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 189
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 187
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 187
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 186
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 183
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 182
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 181
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 179
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 177
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 173
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 172
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 171
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 171
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 171
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 167
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 167
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 166
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 166
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 165
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 165
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 165
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 163
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 163
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 162
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 162
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 161
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 157
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 157
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 156
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 155
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 152
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 151
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 151
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 151
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 150
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 147
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 146
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 145
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 145
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 142
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 141
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 140
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 140
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 139
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 139
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 137
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 136
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 135
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 134
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 133
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 133
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 132
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 127
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 126
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 122
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 118
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 116
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 116
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 115
I tumori nelle provincie di Parma, Reggio Emilia, Modena 108
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 108
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 101
Twenty-years experience with de novo metastatic breast cancer 100
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 99
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 99
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 94
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 94
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) 89
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 85
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 82
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 77
Influence of Type of Fixation and Other Characteristics on Outcome after Endovascular Repair of Ruptured Abdominal Aortic Aneurysms 76
Totale 22.345
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.634 377 208 232 440 459 633 672 445 481 248 251 188
2020/20214.312 350 180 369 436 515 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/2025105 105 0 0 0 0 0 0 0 0 0 0 0
Totale 22.603